CA
NZ
UK
AU
IND
US
● INBX shares gained roughly 17%, recovering ground after a nearly 9% post-earnings drop on heavy volume.
● RYOJ shares took off 20.81% without an obvious, verifiable company-specific catalyst, consistent with the behavior of a small, low-float name.
● ADVB shares rocketed 14.46% without a confirmed corporate catalyst, fitting the stock's established pattern of sharp, momentum-driven bursts.
● BLSM shares jumped 14.91% without a defining company announcement, reflecting a broader lift in risk appetite across biotech.
● GENB shares climbed 15.01% amid a broad re-rating of AI-enabled and computational drug-discovery names, without a single company-specific catalyst.
● MRNA shares rose 14% as investors continued to reward the Phase 3 success of Moderna and Merck's individualized cancerVaccinein melanoma.
● TENX shares jumped 25.41% in a rebound that recovers only a fraction of the value erased when the stock plunged roughly 90% on August 10 after its Phase 3 LEVEL trial missed its primary endpoint.
● AMIX shares broke out roughly 34% after an investor exercised 857,462 warrants at $5.75 per share, generating roughly $4.9 million in gross proceeds.
● CAPR shares surged 21.91% after the FDA agreed to consider an amendedBiologicslicense application for deramiocel centered on upper-limb skeletal muscle function in Duchenne muscular dystrophy.
● Second-quarter 2026Revenuefell about 76% to roughly $4.05 million from $17.08 million a year earlier, while the net loss widened to about $55.4 million from $34.7 million.
Please wait processing your request...